WO2003045901A3 - Guanidine derivatives - Google Patents

Guanidine derivatives Download PDF

Info

Publication number
WO2003045901A3
WO2003045901A3 PCT/GB2003/000339 GB0300339W WO03045901A3 WO 2003045901 A3 WO2003045901 A3 WO 2003045901A3 GB 0300339 W GB0300339 W GB 0300339W WO 03045901 A3 WO03045901 A3 WO 03045901A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
fused
cycloaliphatic
guanidine derivatives
heteroaryl
Prior art date
Application number
PCT/GB2003/000339
Other languages
French (fr)
Other versions
WO2003045901A2 (en
Inventor
Hazel Joan Dyke
George Martin Buckley
Original Assignee
Celltech R&D Ltd
Hazel Joan Dyke
George Martin Buckley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd, Hazel Joan Dyke, George Martin Buckley filed Critical Celltech R&D Ltd
Priority to AU2003202091A priority Critical patent/AU2003202091A1/en
Publication of WO2003045901A2 publication Critical patent/WO2003045901A2/en
Publication of WO2003045901A3 publication Critical patent/WO2003045901A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Guanidine derivatives of formula (I) are described: wherein: R' is an aliphatic, cycloaliphatic or cycloalkyl-alkyl- group; R2 is an optionally substituted aromatic, heteroaromatic group, aryl-fused cycloaliphatic, heteroaryl-fused cycloaliphatic, aryl-fused heterocycloaliphatic or heteroaryl-fused heterocycloaliphatic group; R3 is a -CN, -COR5, -OR6, -CON(R7)R8, S02R5 or S02N(R7)R8 group; R4 is an optionally substituted heteroaromatic group; and the salts, solvates, hydrates, tautomers, isomers, N-oxides thereof. The compounds are potent inhibitors of IMPDH and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatic and anti-viral agents.
PCT/GB2003/000339 2002-04-10 2003-01-28 Guanidine derivatives WO2003045901A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003202091A AU2003202091A1 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208224.6A GB0208224D0 (en) 2002-04-10 2002-04-10 Chemical compounds
GB0208224.6 2002-04-10

Publications (2)

Publication Number Publication Date
WO2003045901A2 WO2003045901A2 (en) 2003-06-05
WO2003045901A3 true WO2003045901A3 (en) 2003-07-31

Family

ID=9934563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000339 WO2003045901A2 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Country Status (3)

Country Link
AU (1) AU2003202091A1 (en)
GB (1) GB0208224D0 (en)
WO (1) WO2003045901A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457716T1 (en) 2002-12-30 2010-03-15 Angiotech Int Ag RELEASE OF ACTIVE INGREDIENTS FROM QUICK-GELLING POLYMER COMPOSITION
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US8034953B2 (en) 2005-05-10 2011-10-11 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
TWI382974B (en) 2005-12-20 2013-01-21 Incyte Corp N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20070203140A1 (en) * 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
JP5319532B2 (en) 2006-09-19 2013-10-16 インサイト・コーポレイション N-hydroxyamidino heterocycle as a modulator of indoleamine 2,3-dioxygenase
PT2315756E (en) 2008-07-08 2014-12-16 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
ES2639439T3 (en) 2010-12-08 2017-10-26 Lycera Corporation Inhibitors of F1F0-ATPases of pyrazolylguanidine type and their therapeutic uses
WO2012078869A1 (en) 2010-12-08 2012-06-14 Lycera Corporation Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
PT3066085T (en) 2013-11-08 2020-07-16 Incyte Holdings Corp Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
EP3080087B1 (en) 2013-12-10 2019-05-22 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2015089131A1 (en) 2013-12-10 2015-06-18 Lycera Corporation Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
CN109970675A (en) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 One group of thiourea compound and its preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO2001004102A1 (en) * 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives
US6420403B1 (en) * 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US6420403B1 (en) * 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
WO2001004102A1 (en) * 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
WO2003045901A2 (en) 2003-06-05
AU2003202091A8 (en) 2003-06-10
AU2003202091A1 (en) 2003-06-10
GB0208224D0 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
WO2003045901A3 (en) Guanidine derivatives
DK0889877T3 (en) Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors
DE60204452D1 (en) [1,5] pyridine derivatives
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
MXPA02012033A (en) 2-aminocarbonyl-9h-purine derivatives.
ATE301653T1 (en) PYRAZOLOPYRIDINES
LV12496A (en) Novel guanidine mimics as factor xa inhibitors
DK2314582T3 (en) Heterocyclic compounds as antiviral agents
FI962155A (en) Novel 9-hydroxypyrido (1,2-a) pyrimidin-4-one ether derivatives
MY129796A (en) Novel anti-inflammatory androstane derivatives
NO20035583D0 (en) Imidazo` 1,2-A pyridine derivatives for prophylaxis and treatment of herpes viral infections
AU2002246728A1 (en) Carboline derivatives
ATE223419T1 (en) CONDENSED THIADIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO2002048148A3 (en) Pyrazolopyridine derivatives
ATE332903T1 (en) CONDENSED PYRIDOINDOLE DERIVATIVES
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
AU2002213419A1 (en) Condensed pyridoindole derivatives
NO983444D0 (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
WO2002026718A3 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP